NASDAQ: EQ
Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies to treat severe autoimmune and inflammatory disorders. Its lead program, EQ504, is a potent and selective aryl hydrocarbon receptor (AhR) modulator with a multi-modal, non-immunosuppressive mechanism of action designed for targeted, local delivery. EQ504 is being developed initially as a colon-targeted oral therapy for ulcerative colitis and other gastrointestinal diseases, with additional development as an inhaled formulation for inflammatory lung diseases. The company is also advancing EQ302, an oral bi-specific inhibitor of IL-15 and IL-21 intended for celiac disease. Equillium trades on Nasdaq under the ticker EQ and is pre-revenue, funding operations through equity capital raises. Updated
These are four stocks for aggressive investors looking to get share count leverage on companies that have sizable upside potential. They are not penny stocks with absolutely no track record or liquidity,…
Equillium, Inc. is a clinical-stage biotechnology company focused on developing therapies to treat severe autoimmune and inflammatory disorders.
